RHOA and breast cancer: It has been reported that dasatinib inhibits the migration and metastasis of canine mammary cancer cells with enhanced Wnt and HER signaling via downregulation of cSRC (Timmermans-Sprang et al., 2019), and inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoA-ROCK Pathway (Dasgupta et al., 2017; Lee et al., 2019).